Philanthropic Contributions Foster Research on Alzheimer's Disease through Goldenrod Therapeutics#United_States#Houston#Alzheimer's_Disease#Goldenrod_Therapeutics #11h_Compound
Philanthropic Contributions Foster Research on Alzheimer's Disease through Goldenrod Therapeutics
Dr. Marie and Mr. Vijay Goradia's generous support is enabling essential research into Alzheimer's via Goldenrod Therapeutics and UT Health.
third-news.com
September 28, 2026 at 1:32 PM
Philanthropic Contributions Foster Research on Alzheimer's Disease through Goldenrod Therapeutics#United_States#Houston#Alzheimer's_Disease#Goldenrod_Therapeutics #11h_Compound
Greg and Ellen Jordan Fund $1 Million to Alzheimer's Care at AHN#United_States#Pittsburgh#Allegheny_Health_Network#Alzheimer's_Disease#Greg_Jordan
Greg and Ellen Jordan Fund $1 Million to Alzheimer's Care at AHN
A generous donation from Greg and Ellen Jordan aims to enhance Alzheimer's care at Allegheny Health Network, supporting innovative research and patient services.
third-news.com
September 28, 2026 at 8:16 PM
Greg and Ellen Jordan Fund $1 Million to Alzheimer's Care at AHN#United_States#Pittsburgh#Allegheny_Health_Network#Alzheimer's_Disease#Greg_Jordan
New Study Links Long COVID to Alzheimer's Disease Mechanisms and Symptoms#USA#New_York#NYU_Langone#Alzheimer's_Disease#Long_COVID
New Study Links Long COVID to Alzheimer's Disease Mechanisms and Symptoms
A recent study reveals that structural changes in the brain caused by Long COVID are linked to Alzheimer's mechanisms, suggesting potential cognitive declines.
third-news.com
February 10, 2026 at 12:12 PM
New Study Links Long COVID to Alzheimer's Disease Mechanisms and Symptoms#USA#New_York#NYU_Langone#Alzheimer's_Disease#Long_COVID
NeuroTherapia to Reveal Promising Findings in Alzheimer's Trial at AAIC 2026#London#UK#Alzheimer's_Disease#NeuroTherapia#NTRX-07
NeuroTherapia to Reveal Promising Findings in Alzheimer's Trial at AAIC 2026
At the AAIC 2026 Conference in London, NeuroTherapia will unveil data from its Phase 2a clinical trial of NTRX-07 for Alzheimer's disease, highlighting significant safety and biomarker results.
third-news.com
July 13, 2026 at 10:14 AM
NeuroTherapia to Reveal Promising Findings in Alzheimer's Trial at AAIC 2026#London#UK#Alzheimer's_Disease#NeuroTherapia#NTRX-07
NeuroSense Therapeutics Achieves Landmark Biomarker Discoveries in Alzheimer's Disease Treatment#USA#Cambridge#Alzheimer's_Disease#NeuroSense#PrimeC
NeuroSense Therapeutics Achieves Landmark Biomarker Discoveries in Alzheimer's Disease Treatment
NeuroSense Therapeutics has announced significant biomarker findings from its Phase 2 Alzheimer's study, supporting its drug PrimeC's multi-target approach.
third-news.com
June 25, 2026 at 2:00 PM
NeuroSense Therapeutics Achieves Landmark Biomarker Discoveries in Alzheimer's Disease Treatment#USA#Cambridge#Alzheimer's_Disease#NeuroSense#PrimeC
Breakthrough Research Validates Remote Testing Technology for Alzheimer's Disease Biomarkers#Sweden#Stockholm#Alzheimer's_Disease#Biomarkers#Capitainer
Breakthrough Research Validates Remote Testing Technology for Alzheimer's Disease Biomarkers
Recent findings highlight a major advancement in Alzheimer's diagnosis. Remote sampling of blood allows effective monitoring of the disease's biomarkers, enhancing accessibility.
third-news.com
May 21, 2026 at 7:52 AM
Breakthrough Research Validates Remote Testing Technology for Alzheimer's Disease Biomarkers#Sweden#Stockholm#Alzheimer's_Disease#Biomarkers#Capitainer
FDA Greenlights Leqembi Iqlik®: A New Era in Early Alzheimer's Treatment#USA#FDA_Approval#Stockholm#Alzheimer's_Disease#LEQEMBI_IQLIK
FDA Greenlights Leqembi Iqlik®: A New Era in Early Alzheimer's Treatment
Eisai announces FDA endorsement for Leqembi Iqlik®, enabling at-home treatment for early Alzheimer's disease, enhancing patient care.
third-news.com
July 14, 2026 at 2:53 AM
FDA Greenlights Leqembi Iqlik®: A New Era in Early Alzheimer's Treatment#USA#FDA_Approval#Stockholm#Alzheimer's_Disease#LEQEMBI_IQLIK
The Breakthrough in Alzheimer's Research: SpeechDx's Role in AI-Driven Detection Tools#USA#New_York#AI_Technology#Alzheimer's_Disease#SpeechDx
The Breakthrough in Alzheimer's Research: SpeechDx's Role in AI-Driven Detection Tools
Explore the latest advancements in Alzheimer's diagnostics through AI and SpeechDx, enabling earlier detection and personalized care in dementia.
third-news.com
June 22, 2026 at 2:35 PM
The Breakthrough in Alzheimer's Research: SpeechDx's Role in AI-Driven Detection Tools#USA#New_York#AI_Technology#Alzheimer's_Disease#SpeechDx
Re:Cognition Health Unveils Groundbreaking Alzheimer’s Diagnostic Clinical Trial with Blood Tests#United_States#Houston#Clinical_Trial#Alzheimer’s_Disease#Re:Cognition_Health
Re:Cognition Health Unveils Groundbreaking Alzheimer’s Diagnostic Clinical Trial with Blood Tests
Re:Cognition Health is initiating a significant clinical trial to assess if a simple finger-prick blood test can lead to earlier Alzheimer's diagnoses.
third-news.com
April 15, 2026 at 3:17 PM
Re:Cognition Health Unveils Groundbreaking Alzheimer’s Diagnostic Clinical Trial with Blood Tests#United_States#Houston#Clinical_Trial#Alzheimer’s_Disease#Re:Cognition_Health
Circular Genomics to Present Groundbreaking Blood Biomarkers for Alzheimer's Disease at CTAD 2025#United_States#San_Diego#Alzheimer's_Disease#Circular_Genomics#circRNA
Circular Genomics to Present Groundbreaking Blood Biomarkers for Alzheimer's Disease at CTAD 2025
Discover how Circular Genomics' innovative circular RNA biomarker platform is revolutionizing early detection of Alzheimer's Disease at CTAD 2025.
third-news.com
November 24, 2025 at 2:37 PM
Circular Genomics to Present Groundbreaking Blood Biomarkers for Alzheimer's Disease at CTAD 2025#United_States#San_Diego#Alzheimer's_Disease#Circular_Genomics#circRNA
Eli Lilly to Unveil Groundbreaking Alzheimer's Research at AAIC 2026#United_States#Indianapolis#Alzheimer's_Disease#Lilly#Kisunla
Eli Lilly to Unveil Groundbreaking Alzheimer's Research at AAIC 2026
Eli Lilly is set to present key findings on Alzheimer's diagnostics and therapies during the AAIC 2026 in London, focusing on P-tau217 blood tests.
third-news.com
July 9, 2026 at 11:36 AM
Eli Lilly to Unveil Groundbreaking Alzheimer's Research at AAIC 2026#United_States#Indianapolis#Alzheimer's_Disease#Lilly#Kisunla
Cure Alzheimer's Fund Achieves a Milestone with 1,000th Research Grant Award#United_States#Alzheimer's_Disease#Wellesley#Alzheimer's_Research#Cure_Alzheimer's_Fund
Cure Alzheimer's Fund Achieves a Milestone with 1,000th Research Grant Award
Cure Alzheimer’s Fund has awarded its 1,000th grant, marking a significant step in research to combat Alzheimer's disease and offer hope for future treatments.
third-news.com
October 7, 2025 at 9:14 AM
Cure Alzheimer's Fund Achieves a Milestone with 1,000th Research Grant Award#United_States#Alzheimer's_Disease#Wellesley#Alzheimer's_Research#Cure_Alzheimer's_Fund
Seth Rogen and Lauren Miller Rogen's Charity Event Raises $1.3M for Alzheimer's Support#USA#Los_Angeles#Alzheimer’s_Disease#Seth_Rogen#Hilarity_for_Charity
Seth Rogen and Lauren Miller Rogen's Charity Event Raises $1.3M for Alzheimer's Support
Seth Rogen and Lauren Miller Rogen hosted a successful fundraiser, 'Friendgiving,' raising $1.3 million for Alzheimer's research and caregiver support.
third-news.com
November 17, 2025 at 12:21 PM
Seth Rogen and Lauren Miller Rogen's Charity Event Raises $1.3M for Alzheimer's Support#USA#Los_Angeles#Alzheimer’s_Disease#Seth_Rogen#Hilarity_for_Charity
TOBY's Groundbreaking Alzheimer's Test Receives FDA Breakthrough Designation to Enhance Diagnostic Care#USA#Austin#FDA#Alzheimer's_Disease#TOBY_Test
TOBY's Groundbreaking Alzheimer's Test Receives FDA Breakthrough Designation to Enhance Diagnostic Care
TOBY, Inc. has achieved a significant milestone with the FDA granting Breakthrough Device Designation for its innovative Alzheimer's diagnostic test, utilizing urine samples for early detection.
third-news.com
May 26, 2026 at 1:42 PM
TOBY's Groundbreaking Alzheimer's Test Receives FDA Breakthrough Designation to Enhance Diagnostic Care#USA#Austin#FDA#Alzheimer's_Disease#TOBY_Test
Egg Consumption Linked to Reduced Alzheimer's Risk in Older Adults: New Study Reveals#USA#Chicago#Alzheimer's_Disease#Nutrition_Study#Egg_Consumption
Egg Consumption Linked to Reduced Alzheimer's Risk in Older Adults: New Study Reveals
A recent study highlights the connection between egg consumption and a lower risk of Alzheimer's disease for older adults, emphasizing the health benefits of dietary eggs.
third-news.com
May 5, 2026 at 2:23 PM
Egg Consumption Linked to Reduced Alzheimer's Risk in Older Adults: New Study Reveals#USA#Chicago#Alzheimer's_Disease#Nutrition_Study#Egg_Consumption
Eisai Unveils Promising Results of Etalanetug for Alzheimer's at AAIC 2026#Japan#Tokyo#Eisai#Alzheimer's_Disease#Etalanetug
Eisai Unveils Promising Results of Etalanetug for Alzheimer's at AAIC 2026
Eisai recently showcased its groundbreaking findings on etalanetug, a potential Alzheimer's treatment, at the AAIC 2026, marking a significant advancement in disease-specific biomarker assessment.
third-news.com
July 13, 2026 at 8:11 AM
Eisai Unveils Promising Results of Etalanetug for Alzheimer's at AAIC 2026#Japan#Tokyo#Eisai#Alzheimer's_Disease#Etalanetug
ALZpath Recognized as One of the World's Top Innovators by Fast Company in 2025#USA#Alzheimer's_Disease#Carlsbad#Fast_Company#ALZpath
ALZpath Recognized as One of the World's Top Innovators by Fast Company in 2025
ALZpath has made it to Fast Company's list of the Most Innovative Companies of 2025 for its groundbreaking diagnostics for Alzheimer's disease.
third-news.com
March 18, 2025 at 11:22 AM
ALZpath Recognized as One of the World's Top Innovators by Fast Company in 2025#USA#Alzheimer's_Disease#Carlsbad#Fast_Company#ALZpath
Circular Genomics Secures $250K from ADDF to Enhance Alzheimer's Detection with CircRNA Biomarkers#United_States#San_Diego#Alzheimer's_Disease#Circular_Genomics#circRNA_Biomarkers
Circular Genomics Secures $250K from ADDF to Enhance Alzheimer's Detection with CircRNA Biomarkers
Circular Genomics has been awarded a $250K investment from the Alzheimer's Drug Discovery Foundation to advance blood-based circRNA biomarker tests for early Alzheimer's detection.
third-news.com
July 8, 2025 at 3:06 PM
Circular Genomics Secures $250K from ADDF to Enhance Alzheimer's Detection with CircRNA Biomarkers#United_States#San_Diego#Alzheimer's_Disease#Circular_Genomics#circRNA_Biomarkers
Collaboration Between Circular Genomics and Altoida to Enhance Alzheimer's Precision Medicine#USA#San_Diego#Alzheimer's_Disease#Circular_Genomics#Altoida
Collaboration Between Circular Genomics and Altoida to Enhance Alzheimer's Precision Medicine
Discover how Circular Genomics and Altoida's partnership aims to transform Alzheimer's diagnostics by combining cutting-edge biomarkers and AI technology.
third-news.com
September 22, 2026 at 10:06 AM
Collaboration Between Circular Genomics and Altoida to Enhance Alzheimer's Precision Medicine#USA#San_Diego#Alzheimer's_Disease#Circular_Genomics#Altoida
Enhancing Tau Tangle Detection with New Biomarker in Upcoming Xtalks Webinar#Canada#Toronto#Alzheimer's_Disease#Tau_Tangle#eMTBR-Tau
Enhancing Tau Tangle Detection with New Biomarker in Upcoming Xtalks Webinar
Join Xtalks' upcoming webinar to discover how plasma eMTBR-Tau, a new biomarker, can enhance the detection of tau tangles in Alzheimer's disease.
third-news.com
September 16, 2026 at 12:33 PM
Enhancing Tau Tangle Detection with New Biomarker in Upcoming Xtalks Webinar#Canada#Toronto#Alzheimer's_Disease#Tau_Tangle#eMTBR-Tau
New Insights into Tau Accumulation Mechanism Revealed by Cell Stress Response Abnormalities in Alzheimer's Disease#Japan#Tokyo#Alzheimer’s_Disease#Tau_Protein#MARK4
New Insights into Tau Accumulation Mechanism Revealed by Cell Stress Response Abnormalities in Alzheimer's Disease
Recent research uncovers a critical relationship between oxidative stress and tau protein accumulation, shedding light on Alzheimer's disease pathology and potential treatments.
third-news.com
September 9, 2026 at 5:30 AM
New Insights into Tau Accumulation Mechanism Revealed by Cell Stress Response Abnormalities in Alzheimer's Disease#Japan#Tokyo#Alzheimer’s_Disease#Tau_Protein#MARK4
Significant Relationship Identified Between Cognitive Function Assessment and VSRAD Testing#Japan#Tokyo#Alzheimer's_Disease#MCI_Screen#VSRAD
Significant Relationship Identified Between Cognitive Function Assessment and VSRAD Testing
A groundbreaking study reveals a strong connection between the MCI Screen and VSRAD, aiding in early Alzheimer's diagnosis.
third-news.com
September 2, 2026 at 9:27 PM
Significant Relationship Identified Between Cognitive Function Assessment and VSRAD Testing#Japan#Tokyo#Alzheimer's_Disease#MCI_Screen#VSRAD
👉Metabolic endotoxemia in metabolic and neurodegenerative diseases
mp.weixin.qq.com/s/yALwNusNpO...
#metabolic_endotoxemia
#lipopolysaccharide
#inflammation
#metabolic_diseases
#Alzheimer’s_disease
mp.weixin.qq.com/s/yALwNusNpO...
#metabolic_endotoxemia
#lipopolysaccharide
#inflammation
#metabolic_diseases
#Alzheimer’s_disease
August 28, 2026 at 6:41 AM
👉Metabolic endotoxemia in metabolic and neurodegenerative diseases
mp.weixin.qq.com/s/yALwNusNpO...
#metabolic_endotoxemia
#lipopolysaccharide
#inflammation
#metabolic_diseases
#Alzheimer’s_disease
mp.weixin.qq.com/s/yALwNusNpO...
#metabolic_endotoxemia
#lipopolysaccharide
#inflammation
#metabolic_diseases
#Alzheimer’s_disease
LEQEMBI IQLIK: A Revolutionary Treatment for Early Alzheimer's Disease Now Available#United_States#Tokyo#Alzheimer's_Disease#LEQEMBI_IQLIK#Eisai_Biogen
LEQEMBI IQLIK: A Revolutionary Treatment for Early Alzheimer's Disease Now Available
LEQEMBI IQLIK, a groundbreaking therapy for early Alzheimer's, offers a convenient at-home administration option. Learn about its benefits.
third-news.com
August 24, 2026 at 12:18 PM
LEQEMBI IQLIK: A Revolutionary Treatment for Early Alzheimer's Disease Now Available#United_States#Tokyo#Alzheimer's_Disease#LEQEMBI_IQLIK#Eisai_Biogen
C2N Diagnostics' PrecivityAD2 Blood Test Pioneers Alzheimer's Detection for Younger Adults#United_States#New_York#Alzheimer’s_Disease#C2N_Diagnostics#PrecivityAD2
C2N Diagnostics' PrecivityAD2 Blood Test Pioneers Alzheimer's Detection for Younger Adults
The FDA's recent approval of C2N Diagnostics' PrecivityAD2 blood test is a groundbreaking step in Alzheimer's detection for adults as young as 40 years, marking a significant leap in precision medicine.
third-news.com
August 20, 2026 at 9:07 PM
C2N Diagnostics' PrecivityAD2 Blood Test Pioneers Alzheimer's Detection for Younger Adults#United_States#New_York#Alzheimer’s_Disease#C2N_Diagnostics#PrecivityAD2